Vitamin B6

What it is

Vitamin B6 is a water-soluble essential micronutrient comprising several related chemical compounds: pyridoxine, pyridoxal, pyridoxamine, and their phosphorylated derivatives [1][2]. The biologically active coenzyme form is pyridoxal 5'-phosphate (PLP), which participates in over 100 enzymatic reactions in human metabolism, particularly protein and amino acid metabolism, neurotransmitter synthesis, and hemoglobin formation [1][2].

Rich dietary sources of vitamin B6 include poultry, fish (such as salmon and tuna), organ meats, potatoes, chickpeas, bananas, and fortified breakfast cereals [1]. In dietary supplements and pharmaceutical preparations, it is most commonly provided as pyridoxine hydrochloride or pyridoxal 5'-phosphate [1][2].

How it might work

Several physiological mechanisms are proposed for how vitamin B6 exerts therapeutic effects in pregnancy nausea and PMS [2][3]. In the nervous system, pyridoxal 5'-phosphate serves as an essential cofactor for aromatic L-amino acid decarboxylase, the enzyme required for the synthesis of serotonin, dopamine, and gamma-aminobutyric acid (GABA) from amino acid precursors [1][3]. Alterations in central neurotransmitter turnover, particularly serotonin and GABA, are thought to contribute to premenstrual mood changes, irritability, and depressive symptoms [4][3].

In pregnancy, lower circulating concentrations of vitamin B6 have been observed in women suffering from nausea and vomiting compared to asymptomatic controls [5]. Active PLP is hypothesised to modulate neurochemical signaling in the chemoreceptor trigger zone and gastrointestinal autonomic pathways [2]. In clinical pharmacokinetics, oral pyridoxine is rapidly converted into circulating PLP, whose steady-state concentrations correlate directly with improvements in pregnancy emesis scores [2].

What the research says

Randomised trials and systematic reviews indicate moderate therapeutic benefits of vitamin B6 for pregnancy nausea and premenstrual syndrome [6][4].

For pregnancy nausea, a 2015 Cochrane systematic review of 41 trials (5,449 women) found evidence supporting the use of pyridoxine to relieve mild to moderate nausea in early pregnancy [6]. In a double-blind trial of 342 pregnant women, oral pyridoxine hydrochloride at 30 mg daily for 5 days significantly reduced nausea scores compared with placebo (p = 0.0008), though reductions in vomiting did not achieve statistical significance (p = 0.0552) [7]. In another double-blind trial in 59 women, 25 mg every 8 hours (75 mg daily) for 72 hours significantly improved severe nausea compared to placebo (mean reduction 4.3 vs 1.8, p < 0.01) and reduced the proportion of women vomiting from 15 of 31 to 8 of 31 (p < 0.05) [8]. A trial comparing 80 mg daily of vitamin B6 against ginger and placebo in 77 women found that both active treatments significantly decreased Rhodes nausea and vomiting scores compared to placebo (p = 0.007 for B6) [9]. In combination with the antihistamine doxylamine (10 mg each, up to 4 tablets daily), pyridoxine significantly lowered Pregnancy-Unique Quantification of Emesis (PUQE) scores in 256 pregnant women compared to placebo (-4.8 vs -3.9, p = 0.006) [10].

For premenstrual syndrome, a systematic review of nine randomised placebo-controlled trials involving 940 women demonstrated an odds ratio of 2.32 (95% CI 1.95 to 2.54) for overall PMS symptom improvement with vitamin B6 over placebo [4]. For premenstrual depressive symptoms, the pooled odds ratio was 1.69 (95% CI 1.39 to 2.06) across four trials with 541 patients [4]. A 2024 systematic review of 31 randomised trials (3,254 women) confirmed consistent, statistically significant positive effects of vitamin B6 on psychological symptoms of PMS [3]. In a randomised trial evaluating 78 women over three menstrual cycles, daily supplementation with 80 mg of vitamin B6 produced medium effect sizes on symptom reduction (0.43 to 0.56) and resulted in full symptom remission in 60% of participants [11]. A trial in 434 women in primary care similarly reported significantly greater global symptom improvement after three cycles with pyridoxine than with placebo (p < 0.02) [12].

Doses used in studies

In clinical trials for pregnancy-induced nausea, oral pyridoxine hydrochloride is typically administered at doses of 10 to 25 mg taken three times daily (totaling 30 to 75 mg per day) for 3 to 14 days [7][8]. When formulated in delayed-release combinations with doxylamine, 10 to 40 mg daily of pyridoxine is standardly used [10].

In studies investigating premenstrual syndrome, doses have ranged from 50 to 100 mg daily administered continuously across the menstrual cycle or targeted to the luteal phase for two to three cycles [4][11]. Trials using higher intakes between 150 and 300 mg daily found no additional symptomatic benefit and increased the likelihood of adverse side effects [13][14].

Safety and interactions

At standard nutritional doses, vitamin B6 has a high safety margin [1]. However, excessive supplemental doses can cause serious neurological toxicity [15][16]. Chronic consumption of high doses of pyridoxine—typically exceeding 100 to 200 mg daily for several months, and in some individuals at doses above 50 mg daily—can cause sensory peripheral neuropathy and neuronopathy [15][16]. Symptoms include numbness, tingling (paresthesia), burning pain, diminished vibration and position sense, and difficulty with balance and walking (sensory ataxia) [16][17]. While symptoms frequently improve following supplement discontinuation, recovery may be slow and incomplete after protracted high-dose exposure [16][15].

The tolerable upper intake level (UL) established by the United States Institute of Medicine is 100 mg daily for adults [15]. European regulatory authorities recommend even lower chronic upper limits (12 to 25 mg daily) based on neurotoxicity reports [15]. Common non-neurological side effects at higher doses include mild gastrointestinal upset, nausea, headache, and somnolence [10][1].

Several important drug interactions are documented. Pyridoxine stimulates the peripheral decarboxylation of levodopa, significantly reducing its uptake into the central nervous system and diminishing its therapeutic effectiveness in Parkinson's disease; this interaction does not occur when levodopa is co-administered with a peripheral dopa-decarboxylase inhibitor such as carbidopa [18]. Pyridoxine supplementation can also lower circulating serum concentrations of antiepileptic medications, notably phenytoin and phenobarbital, potentially reducing seizure control [19]. Conversely, medications such as isoniazid, penicillamine, and oral contraceptives can deplete body stores of vitamin B6 or interfere with its metabolism [1].

During pregnancy and breastfeeding, dietary intake within nutritional recommendations is safe and essential [1]. Therapeutic use of pyridoxine at 30 to 75 mg daily for nausea in early pregnancy has been widely evaluated in clinical trials and extensive observational registries without evidence of maternal or fetal harm [10][6]. However, excessive doses during pregnancy should be strictly avoided [15].

Caveats and open questions

Several limitations and open questions remain regarding vitamin B6 supplementation [4][6]. First, many early trials evaluating vitamin B6 for PMS were small, lacked standardised diagnostic criteria, and had high or unclear risks of bias and substantial placebo responses [4][3]. While modern systematic reviews support a psychological benefit, high-quality contemporary trials adhering to modern CONSORT standards remain limited [3].

Second, in pregnancy nausea, pyridoxine shows a stronger and more consistent effect on nausea intensity than on actual vomiting frequency or hyperemesis gravidarum [7][6]. The optimal dosing schedule (divided daily doses vs delayed-release formulations) and comparative efficacy against other antiemetics like ginger require further large-scale head-to-head trials [9][6]. Finally, whether pyridoxal 5'-phosphate (P5P) offers superior therapeutic efficacy or lower neurotoxicity compared to standard pyridoxine hydrochloride in humans has not been established in definitive comparative clinical trials [2].